Tectonic Therapeutic has shown promising Phase 1b data for its TX45 drug targeting pulmonary hypertension in heart failure patients, supported by external Merck trial results. The company’s financial position is strong, with cash to fund operations through early 2029, lowering near-term financing concerns. Another candidate, TX2100, is progressing with Phase 1a results expected by Q3 2026, further validating their drug platform. Key upcoming catalysts include data releases for APEX and TX2100 in 2026–2027, making Tectonic an attractive option for biotech investors seeking growth with reduced risk.
Hyperliquid Strategies expanded its equity financing facility with Chardan Capital Markets from $1 billion to $2.5 billion, allowing it to sell more shares over time to fund general corporate purposes, including potential purchases of its native toke...
A joint study by ARK Invest and Glassnode found Bitcoin's mining power is concentrated in three pools surpassing 51% hash rate, but independent miners can switch pools quickly, limiting control. Ethereum requires three staking entities to exceed a 33...
Two Thai businessmen sued Tether in New York, challenging the company's authority to freeze about $42.4 million USDT in October 2025 without a court warrant. The freeze followed an informal request from Homeland Security Investigations amid a broader...
US federal debt has surpassed $40 trillion, driven by significant government and corporate borrowing to fund a large-scale AI data center infrastructure expansion. Despite high debt levels, the economy remains strong with a 4.1% unemployment rate in ...
Dogwood Therapeutics, a clinical-stage biotech company, highlighted progress on Halneuron, a NaV1.7 inhibitor aimed at treating chemotherapy-induced neuropathic pain. The company also announced plans to start clinical trials for SP16, an LRP1 agonist...
